Status: Recruiting

Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma

To learn if sacituzumab tirumotecan can help to control advanced or metastatic SMARCB1-deficient RMC in patients whose disease has progressed after receiving at least 1 treatment.

Participants needed: 20

Trial details

Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Sep 24, 2026Locations: 1

Eligibility criteria

Participants with locally advanced or metastatic RMC histologically confirmed by... [+18]

Participants must not have any other malignancies within the past 2 years except... [+24]

Status: Not yet recruiting

A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)

To evaluate the safety and effectiveness of Ivonescimab combined with intraperitoneal paclitaxel (IP PTX) in patients with unresectable metastatic high-grade Appendiceal Adenocarcinoma (AA).

Participants needed: 30

Trial details

Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Aug 27, 2026Locations: 1

Eligibility criteria

Age 18 years and above. There will be no upper age restriction [+22]

Metastases outside the peritoneal cavity, with exception of limited metastases t... [+29]

Status: Not yet recruiting

Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative Neoplasms

To learn if imetelstat can help to control MDS/MPNs.

Participants needed: 30

Trial details

Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Apr 24, 2026Locations: 1

Eligibility criteria

Age ≥18 years as MF and CMML are very rare diseases in the pediatric population. [+16]

Participants who are currently receiving treatment for a malignancy (not includi... [+8]